Wordt geladen...

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Corbin, Amie S., Agarwal, Anupriya, Loriaux, Marc, Cortes, Jorge, Deininger, Michael W., Druker, Brian J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Clinical Investigation 2010
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3007128/
https://ncbi.nlm.nih.gov/pubmed/21157039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI35721
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!